ST Landfar plans to acquire 51% equity of Huize Pharmaceutical, which is expected to constitute a significant asset restructuring situation
I'm PortAI, I can summarize articles.
Landfar plans to acquire 51% equity of Hunan Huize Pharmaceutical in cash, which is expected to constitute a major asset reorganization. After the transaction, Huize Pharmaceutical will become a subsidiary and be included in the consolidated financial statements. Huize Pharmaceutical focuses on drug research and development as well as clinical evaluation, providing pharmaceutical research, clinical trials, and other services. This acquisition aims to enhance the profitability and risk resistance of the biopharmaceutical sector and improve the company's operational efficiency
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments